Shore Capital reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Friday morning, Digital Look reports.
AZN has been the subject of several other research reports. Deutsche Bank restated a buy rating and issued a GBX 8,300 ($108.45) target price on shares of AstraZeneca in a research note on Wednesday, November 13th. JPMorgan Chase & Co. set a GBX 7,900 ($103.23) target price on shares of AstraZeneca and gave the stock a buy rating in a research note on Friday, November 8th. Bank of America restated a buy rating and issued a GBX 8,500 ($111.07) target price on shares of AstraZeneca in a research note on Tuesday, October 8th. Kepler Capital Markets raised their target price on shares of AstraZeneca from GBX 7,700 ($100.61) to GBX 8,000 ($104.53) and gave the stock a buy rating in a research note on Tuesday, October 29th. Finally, UBS Group restated a sell rating and issued a GBX 5,800 ($75.79) target price on shares of AstraZeneca in a research note on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of GBX 7,585.67 ($99.12).
AZN stock opened at GBX 7,458 ($97.45) on Friday. AstraZeneca has a one year low of GBX 109.51 ($1.43) and a one year high of GBX 8,227.88 ($107.51). The stock has a market capitalization of $97.84 billion and a PE ratio of 46.79. The company has a debt-to-equity ratio of 148.59, a quick ratio of 0.70 and a current ratio of 0.92. The company has a fifty day moving average of GBX 7,238.86 and a 200-day moving average of GBX 6,795.93.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Options Trading – Understanding Strike Price
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.